News
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets
Helsinn closes financing agreement with Oberland Capital
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
Helsinn closes financing agreement with Oberland Capital

Sintetica establishes US entity
COMUNICATO STAMPA – Waldo Mossi eletto Vicepresidente di Farma Industria Ticino per il triennio 2022-2025
Comunicato Stampa “Farma Industria Ticino and Credit Suisse Award for best student”

Linkedin